Ipsen Pharma conducted a buy-back program from June 15 to June 19, 2026, purchasing a total of 28,105 of its own shares. The daily average purchase price ranged around €155 to €157 per share on the Euronext Paris market. This buy-back is part of Ipsen's ongoing strategy to manage its capital and potentially support its stock price. Investors should watch for further updates on the program and its impact on Ipsen's share value and capital structure.
Roper Technologies is now considered a cautious Buy, trading about 10% below its intrinsic value following a recent share price recovery. The company reported Q2 2026 results with 8.5% revenue growth and a 233% increase in earnings per share, driven ...
Prysmian is well-positioned to benefit from the expansion of AI-driven data centers and power grids by supplying essential power and optical connectivity infrastructure. The company has a strong backlog of €17 billion in transmission projects, a prop...
Grayscale Investments highlights factors supporting Bitcoin as a long-term investment despite recent price weakness. Key points include ongoing structural growth in Bitcoin adoption driven by government deficits, blockchain integration, and younger i...
Solana (SOL) surged 6.6% to $82.23 on August 19, 2026, driven by US Treasury's doubled bond buybacks, new SEC crypto rules, and a White House crypto summit. The rise also benefited from increased meme coin trading on Solana's platform and Ethereum's ...
Walmart is introducing a new clothing line called Scenario, priced mostly under $25, aimed at younger consumers to regain market share from Amazon. The move reflects Walmart's shift towards offering more stylish and higher-priced apparel to meet cust...
